VRXA (Veraxa Biotech Holding AG) Earnings Power Value (EPV): $-0.00 (As of Dec25)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRXA Veraxa Biotech Holding AG VRXA
6 GF Score
Price $1.77
! 2 Warning Signs
View Full Analysis

What is Veraxa Biotech Holding AG Earnings Power Value (EPV)?

Veraxa Biotech Holding AG VRXA -10.66% 6 Earnings Power Value (EPV) is $-0.00 as of Dec25. GuruFocus rates VRXA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review.

As of Dec25, Veraxa Biotech Holding AG's earnings power value is $-0.00. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Veraxa Biotech Holding AG  (NAS:VRXA) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Veraxa Biotech Holding AG Earnings Power Value (EPV) Related Terms


Veraxa Biotech Holding AG Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for Veraxa Biotech Holding AG's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veraxa Biotech Holding AG Earnings Power Value (EPV) Chart

Veraxa Biotech Holding AG Annual Data
Trend Dec23 Dec24 Dec25
Earnings Power Value (EPV)
0.00 0.00 0.00

Veraxa Biotech Holding AG Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Earnings Power Value (EPV) 0.00 0.00 0.00 0.00 0.00

VRXA vs TTRX, IRD, IFRX: Earnings Power Value (EPV) Comparison

For the Biotechnology subindustry, Veraxa Biotech Holding AG's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veraxa Biotech Holding AG Earnings Power Value (EPV) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Veraxa Biotech Holding AG's Earnings Power Value (EPV) falls into.


VRXA
6GF Score
Veraxa Biotech Holding AG VRXA
Earnings Power Value (EPV) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veraxa Biotech Holding AG Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

What does a Earnings Power Value (EPV) of $-0.00 mean?
Veraxa Biotech Holding AG (VRXA) has a Earnings Power Value (EPV) of $-0.00 as of Dec25. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Veraxa Biotech Holding AG and its competitors.
Is Veraxa Biotech Holding AG's Earnings Power Value (EPV) too high?
Veraxa Biotech Holding AG's current Earnings Power Value (EPV) is $-0.00. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's Earnings Power Value (EPV) compare to TTRX and IRD?
Veraxa Biotech Holding AG's Earnings Power Value (EPV) of $-0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Biotechnology company?
A good Earnings Power Value (EPV) depends on the Biotechnology industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Veraxa Biotech Holding AG and its competitors. Veraxa Biotech Holding AG's current Earnings Power Value (EPV) is $-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current Earnings Power Value (EPV) of $-0.00. The current Earnings Power Value (EPV) is $-0.00. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current Earnings Power Value (EPV) is $-0.00 as of Dec25. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veraxa Biotech Holding AG Business Description

Other Exchanges J8L0:Germany
Address Talacker 35, Zurich, CHE, 8001
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score

Get the complete analysis for VRXA

Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.77
Price